Bharat Biotech conducting clinical trial for immunogenicity of Covaxin booster dose
The efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19 cases
The efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19 cases
0 Comments
Post a Comment